Bibliography
- Bianco C, Strizzi L, Normanno N, et al. Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol 2005;67:85-133
- Strizzi L, Bianco C, Normanno N, Salomon D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene 2005;24(37):5731-41
- Bianco C, Normanno N, Salomon DS, Ciardiello F. Role of the cripto (EGF-CFC) family in embryogenesis and cancer. Growth Factors 2004;22(3):133-9
- Schier AF. Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol 2003;19:589-621
- Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci 2001;6:D685-707
- Bianco C, Strizzi L, Rehman A, et al. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 2003;63(6):1192-7
- Bianco C, Adkins HB, Wechselberger C, et al. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol 2002;22(8):2586-97
- Adkins HB, Bianco C, Schiffer SG, et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 2003;112(4):575-87
- Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA 2003;100(9):5193-8
- Gray PC, Shani G, Aung K, et al. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Mol Cell Biol 2006;26(24):9268-78
- Normanno N, De Luca A, Maiello MR, et al. Cripto-1: a novel target for therapeutic intervention in human carcinoma. Int J Oncol 2004;25(4):1013-20
- De Luca A, Arra C, D'Antonio A, et al. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 2000;19(51):5863-71
- Ciardiello F, Tortora G, Bianco C, et al. Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene 1994;9(1):291-8
- Xing PX, Hu XF, Pietersz GA, et al. Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res 2004;64(11):4018-23
- Hu XF, Li J, Yang E, et al. Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer 2007;96(6):918-27
- Hu XF, Xing PX. Cripto as a target for cancer immunotherapy. Expert Opin Ther Targets 2005;9(2):383-94
- Lowy D. Human papillomavirus, cervical cancer prevention, and more. Vaccine 2008;26(Suppl 10):iii-iv
- Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1(9):751-61
- Alexander J, Fikes J, Hoffman S, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res 1998;18(2):79-92
- Almagro JC, Fransson J. Humanization of antibodies. Front Biosci 2008;13:1619-33